Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy - Wikidata - awgldk - TriplyDB

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy

http://www.wikidata.org/entity/Q29620534

about

PPAR-γ agonists and their effects on IGF-I receptor signaling: Implications for cancer Sulfonylurea versus metformin monotherapy in patients with type 2 diabetes: a Cochrane systematic review and meta-analysis of randomized clinical trials and trial sequential analysis Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).The management of gestational diabetes Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review Metformin and body weight Cardiovascular outcomes in trials of oral diabetes medications: a systematic review Insulin secretagogues for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus Sulphonylurea monotherapy for patients with type 2 diabetes mellitus Sulphonylurea monotherapy for patients with type 2 diabetes mellitus Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus Rosiglitazone for type 2 diabetes mellitus The role of peroxisome proliferator-activated receptors in carcinogenesis and chemoprevention Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes Pioglitazone acutely reduces insulin secretion and causes metabolic deceleration of the pancreatic beta-cell at submaximal glucose concentrations Drugs acting on SUR1 to treat CNS ischemia and trauma Regulatory challenges for new drugs to treat obesity and comorbid metabolic disorders Cardiovascular safety of anti-diabetic drugs Metabolic Inflammation-Differential Modulation by Dietary Constituents The Association between Sulfonylurea Use and All-Cause and Cardiovascular Mortality: A Meta-Analysis with Trial Sequential Analysis of Randomized Clinical Trials An Update on the Effect of Incretin-Based Therapies on β-Cell Function and Mass Metformin revisited: Does this regulator of AMP-activated protein kinase secondarily affect bone metabolism and prevent diabetic osteopathy Patient considerations in type 2 diabetes - role of combination dapagliflozin-metformin XR Early Treatment with Basal Insulin Glargine in People with Type 2 Diabetes: Lessons from ORIGIN and Other Cardiovascular Trials Polypharmacy in the Aging Patient: A Review of Glycemic Control in Older Adults With Type 2 Diabetes Drugs for type 2 diabetes: role in the regulation of bone metabolism Place of sulfonylureas in the management of type 2 diabetes mellitus in South Asia: A consensus statement Treatment of prediabetes Advances in the Science, Treatment, and Prevention of the Disease of Obesity: Reflections From a Diabetes Care Editors' Expert Forum Cardiovascular Risk in Diabetes Mellitus: Complication of the Disease or of Antihyperglycemic Medications Avoiding hypoglycemia: a key to success for glucose-lowering therapy in type 2 diabetes Assessment of pancreatic β-cell function: review of methods and clinical applications Interventions to preserve beta-cell function in the management and prevention of type 2 diabetes Deciding oral drugs after metformin in type 2 diabetes: An evidence-based approach Nuclear receptors in bone physiology and diseases Basal insulin combined incretin mimetic therapy with glucagon-like protein 1 receptor agonists as an upcoming option in the treatment of type 2 diabetes: a practical guide to decision making Systematic reviews to ascertain the safety of diabetes medications

P2860

Q21328702-C907033D-6C62-4E80-A262-0AA9A52F0E42 Q22241119-35283044-C2C2-4C4C-87CC-CCCE3C058ECE Q22241134-FB370815-B091-4EF3-895F-A7F71169EFDD Q22241288-05B697C6-6C63-4260-8E74-C8A07F0137AB Q22241441-2512AD76-C1B1-4593-BB0C-C528EA77B5A7 Q22242077-12E34B37-DF15-46C0-83DC-EB4C846A942C Q22250988-6157286F-93FB-4AD4-A110-6FAAA708DDE9 Q22253058-26688575-9133-4655-B48B-53F3B0B70468 Q24185970-612A37DC-CC61-4636-91B0-5F4CF1737864 Q24186660-0360DB32-9E68-4DE4-B857-DC9583EADFE2 Q24197884-0B6D2DF8-F328-4B00-AAF7-BDBDD6DF7D3E Q24235718-0BED5846-81F9-4014-93D4-13A8E7B7770C Q24240522-0432F881-FF9B-4293-A850-2327BCBCF1FC Q24243875-47D4C643-821E-4102-9E53-F541ABF6068A Q24601222-3DEE8461-23E9-4067-B130-001F9F2ACAD7 Q24628988-11DBCC37-6ECA-40AD-8EB2-10C0B4FB15B4 Q24642503-C146A38F-FEEA-4041-8F4C-888C3A1920D3 Q24642826-076DC385-4ACD-4EF1-916F-DAAA13AF3794 Q24655850-EA08CD70-167F-45DB-AA66-CC251B4C7AEE Q24658031-F4DEB011-8198-4CE8-9C06-C82DEE4B0D84 Q26741082-1851AE19-CE63-4052-A517-B4C11D2E9AE6 Q26748868-85E3C807-D509-4592-945C-4609903D1433 Q26748870-609E9EDB-EAED-4B49-B0C6-82826628D110 Q26749089-DF8DD9D5-EC14-4AB8-BC86-2C21F302A28B Q26750278-15A813C7-8969-47A1-A662-12AB69C9BB66 Q26766404-7D7B9075-7731-4712-BE99-CACDE2A9501E Q26767164-412F7430-2BE6-4EC2-AF14-2EFFCE7F2317 Q26767283-AC4470C8-8859-449F-9275-047A1F2ABC05 Q26775763-35009B44-9BD9-400E-BCE1-295824D85DD3 Q26783199-CBB714CA-DF41-4225-9A6D-C5A6A60178DB Q26783350-082AE7A4-FA80-4ADE-B6B1-7B863F2A28E1 Q26784022-6FEC6E7F-3A06-4F5C-940B-1C54BC17AEB8 Q26824616-655D47C3-3430-45D9-827F-08DF9A70DDCE Q26827955-2AC8B0A3-16AA-4BEA-AA6C-CE656CF7DDB3 Q26829445-58659C35-8946-4F66-BB23-F079D0273406 Q26830871-87B658A0-F69B-400F-A39D-2DB821F5BDA7 Q26851797-C071CCA6-033E-4763-A787-4E8EC09576A7 Q26853017-F0C7A909-BA95-423D-BB49-A1F63D4E4218 Q26992979-55F81A50-EE17-4AF9-A811-5D105E1C6A5D Q27000766-BEB9C96F-7AE9-43B3-AEEB-ABE9886F6D20

P2860

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy

http://www.wikidata.org/entity/Q29620534

description

2006 nî lūn-bûn

@nan

2006 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy

@ast

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy

@en

type

label

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy

@ast

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy

@en

prefLabel

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy

@ast

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy

@en

P1433

Q29620534-24C06EA9-2045-42E5-AFCC-72FAA6FA7B49

P1476

Q29620534-95EA403B-78C9-4BC5-96C5-0675533DD59E

P2093

Q29620534-00AE2312-9A3D-4141-A855-CFC44EAC29A5

Q29620534-0452F760-E713-48A8-B436-CF50E261CA9B

Q29620534-278A2ABC-BDE5-4493-AB62-350812A1D443

Q29620534-468AEE1B-5F12-443C-99E5-5BFD8ACBC107

Q29620534-5C39CF94-AE97-487B-81AB-97CC865A3936

Q29620534-60CDF135-92A0-45DD-9D20-3E335C235619

Q29620534-894767E6-73D3-4F3D-8E10-7659FCD1E02A

Q29620534-A7789E58-4BFA-43F7-BDD7-2D7EDDAE7679

Q29620534-D6ACFD86-84AF-4C53-9F6D-251A6D5E9372

Q29620534-E99FFE57-BC8A-48C3-95CB-9A6CCB24CED9

P304

Q29620534-BA624012-3253-4DCF-9D9F-E62FAB482477

P31

Q29620534-9141E3FD-A4DA-4EFC-BE64-9F87C10573FC

P3181

Q29620534-2E788884-E5E8-43ED-A2FA-1B476B25C297

P356

Q29620534-2934EDD2-A965-4E9C-8CA5-A734C76279F9

P407

Q29620534-3A35DB67-5814-4DFB-906D-C9C9FD4877C2

P433

Q29620534-F441DBFA-B6EC-420C-B5BD-145A2CB13509

P478

Q29620534-80FF3436-B90A-40A7-ADC5-E0F337115A54

P577

Q29620534-743D8C1E-BAFA-49E5-AE3F-A0EAD4C9F514

P698

Q29620534-982B4118-271E-493A-955A-4ADE25B889C2

P921

Q29620534-B9C97B97-8608-4C9A-A8D0-4C830D573283

P3181

P356

P1433

The New England Journal of Medicine

P1476

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy

@en

P2093

Haffner SM

http://www.w3.org/2001/XMLSchema#string

Heise MA

http://www.w3.org/2001/XMLSchema#string

Herman WH

http://www.w3.org/2001/XMLSchema#string

Holman RR

http://www.w3.org/2001/XMLSchema#string

Jones NP

http://www.w3.org/2001/XMLSchema#string

Kahn SE

http://www.w3.org/2001/XMLSchema#string

Kravitz BG

http://www.w3.org/2001/XMLSchema#string

Lachin JM

http://www.w3.org/2001/XMLSchema#string

O'Neill MC

http://www.w3.org/2001/XMLSchema#string

Viberti G

http://www.w3.org/2001/XMLSchema#string

P304

2427-43

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1768157

http://www.w3.org/2001/XMLSchema#string

P356

10.1056/NEJMOA066224

http://www.w3.org/2001/XMLSchema#string

P407

P433

23

http://www.w3.org/2001/XMLSchema#string

P478

355

http://www.w3.org/2001/XMLSchema#string

P577

2006-12-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

17145742

http://www.w3.org/2001/XMLSchema#string

P921